CDK9 Antikörper

Produktnummer ABIN233827

Hersteller Produkt- Nr.: 600-401-996

Produktdetails anti-CDK9 Antikörper

Target: CDK9 (Cyclin-Dependent Kinase 9 (CDK9))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CDK9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunoprecipitation (IP)

Hersteller Produkt- Nr.: 600-401-996

Hersteller: Rockland

Verwendungszweck: CDK9 phospho T29 Antibody

Kreuzreaktivität (Details): This antibody is specific for human CDK9 protein phosphorylated at T29.

Produktmerkmale: Synonyms: rabbit anti-CDK9 pT29 antibody, Cell division protein kinase 9, Cyclin-dependent kinase 9, Serine/threonine-protein kinase PITALRE, Cell division cycle 2-like protein kinase 4, C-2K, Tat-associated kinase complex catalytic subunit, CDC2L4, TAK

Aufreinigung: This product was affinity purified from monospecific antiserum by immunoaffinity chromatography using phospho-peptide coupled to agarose beads followed by solid phase adsorption against nonphospho-peptide.

Sterilität: Sterile filtered

Immunogen:

Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to residues surrounding T29 in the human CDK9 protein.

Immunogen Type: Conjugated Peptide

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

Application Note: This affinity purified antibody has been tested for use in ELISA and western blotting.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 42 kDa in size corresponding to phosphorylated CDK9 protein by western blotting in the appropriate cell lysate or extract.  This phospho-specific polyclonal antibody reacts with human CDK9 pT29 and shows minimal reactivity by ELISA against the non-phosphorylated form of the immunizing peptide.

Western Blot Dilution: 1:200 - 1:2,000

Immunoprecipitation Dilution: 1:100

ELISA Dilution: 1:5,000 - 1:24,000

Other: User Optimized

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.3 mg/mL

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Stabilizer: None

Preservative: 0.01 % (w/v) Sodium Azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store vial at -20° C prior to opening.  Aliquot contents and freeze at -20° C or below for extended storage.  Avoid cycles of freezing and thawing.  Centrifuge product if not completely clear after standing at room temperature.  This product is stable for several weeks at 4° C as an undiluted liquid.  Dilute only prior to immediate use.

Haltbarkeit: 12 months

Details zu CDK9

Target: CDK9 (Cyclin-Dependent Kinase 9 (CDK9))

Andere Bezeichnung: CDK9 (CDK9 Produkte)

Hintergrund: Background: This antibody is designed, produced, and validated as part of a collaboration with the National Cancer Institute (NCI). CDK9 (PITALRE) is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2 and are known as important cell cycle regulators. CDKs are heteromeric serine/threonine kinases that control progression through the cell cycle in concert with their regulatory subunits, the cyclins. Although there are 12 different cdk genes, only 5 have been shown to directly drive the cell cycle. CDK9 (PITALRE) interacts with a conserved domain in the TRAF-C region of the tumor necrosis factor signal transducer TRAF2. This kinase was also found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. It promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis. P-TEFb is also involved in co-transcriptional histone modification, mRNA processing, and mRNA export. It modulates a complex network of chromatin modifications including histone H2B mono-ubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3. It integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing. CDK9 forms a complex with, and is regulated by, its regulatory subunit, cyclin T or cyclin K. The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro. The CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage. In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6. CDK9 promotes cardiac myocyte enlargement. The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation. HIV-1 Tat protein has been found to interact with this protein and cyclin T, which suggested a possible involvement of this protein in AIDS.

Gen-ID: 1025, 4502747

UniProt: P50750

Pathways: Zellzyklus